Further findings linking SSRIs during pregnancy and persistent pulmonary hypertension of the newborn: Clinical implications

CNS Drugs

Volumn 26, Issue 10, 2012, Pages 813-822

  Galbally, Megan ^a   Gentile, Salvatore ^b,c   Lewis, Andrew J ^d  

^a MERCY HOSPITAL FOR WOMEN   (Australia)

^b ASL Salerno   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d DEAKIN UNIVERSITY   (Australia)

Author keywords

Anti depressants; Depression; Infants; Neonates; Pregnancy; Pulmonary hypertension; Serotonin uptake inhibitors.

Indexed keywords

FLUOXETINE; SEROTONIN UPTAKE INHIBITOR;

BODY MASS; CESAREAN SECTION; DRUG EFFICACY; DRUG SAFETY; ECHOCARDIOGRAPHY; ENVIRONMENTAL EXPOSURE; HUMAN; INFORMED CONSENT; LOW BIRTH WEIGHT; MATERNAL SMOKING; MEDICAL RECORD; NEWBORN CARE; NEWBORN DISEASE; NONHUMAN; PERSISTENT PULMONARY HYPERTENSION OF THE NEWBORN; PREGNANCY; PREGNANCY COMPLICATION; PRENATAL EXPOSURE; PRIORITY JOURNAL; PUERPERAL DEPRESSION; PULMONARY HYPERTENSION; RESPIRATORY DISTRESS; REVIEW; THIRD TRIMESTER PREGNANCY;

FEMALE; HUMANS; HYPERTENSION, PULMONARY; INFANT, NEWBORN; PERSISTENT FETAL CIRCULATION SYNDROME; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS;

EID: 84865854703     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11630310-000000000-00000     Document Type: Review

References (50)

1. Hernandez-Diaz S, Van Marter LJ, Werler MM, et al. Risk factors for persistent pulmonary hypertension of the newborn. Pediatrics 2007; 120 (2): e272-82
2. Farrow KN, Fliman P, Steinhorn RH. The diseases treated with ECMO: focus on PPHN. Semin Perinatol 2005; 29 (1): 8-15
3. Occhiogrosso M, Omran SS, AltemusM. Persistent pulmonary hypertension of the newborn and selective serotonin reuptake inhibitors: lessons from clinical and translational studies. Am J Psychiatry 2012 Feb; 169 (2): 134-40
4. Graves E, Redmond C, Arensman RM. Persistent pulmonary hypertension in the neonate. Chest 1988; 93 (3): 638-41
5. Field D, Davis C, Elbourne D, et al. UK collaborative randomised trial of neonatal extracorporeal membrane oxygenation. Int J Gynecol Obstet 1996; 55 (3): 314-5
6. Hansen AK, Wisborg K, Uldbjerg N, et al. Risk of respiratory morbidity in term infants delivered by elective caesarean section: cohort study. BMJ 2008; 336 (7635): 85-7
7. Hansen AK, Wisborg K, Uldbjerg N, et al. Elective caesarean section and respiratory morbidity in the term and nearterm neonate. Acta Obstet Gynecol Scand 2007; 86 (4): 389-94
8. Maschi S, Clavenna A, Campi R, et al. Neonatal outcome following pregnancy exposure to antidepressants: a prospective controlled cohort study. BJOG 2008 Jan; 115 (2): 283-9
9. Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006 Feb 9; 354 (6): 579-87
10. Fornaro E, Li D, Pan J, et al. Prenatal exposure to fluoxetine induces fetal pulmonary hypertension in the rat. Am J Respir Crit Care Med 2007 Nov 15; 176 (10): 1035-40
11. Lim K, Sanders A, Brain U, et al. Third trimester fetal pulmonary artery Doppler blood flow velocity characteristics following prenatal selective serotonin reuptake inhibitor (SSRI) exposure. Early Hum Dev 2012; 88 (8): 609-15
12. Chambers CD, Johnson KA, Dick LM, et al. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996 Oct 3; 335 (14): 1010-5
13. Kallen B, Olausson PO. Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf 2008 Aug; 17 (8): 801-6
14. Reis M, Kallen B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med 2010 Oct; 40 (10): 1723-33
15. Wichman CL, Moore KM, Lang TR, et al. Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy. Mayo Clin Proc 2009; 84 (1): 23-7
16. Andrade SE, McPhillips H, Loren D, et al. Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf 2009 Mar; 18 (3): 246-52
17. Wilson KL, Zelig CM, Harvey JP, et al. Persistent pulmonary hypertension of the newborn is associated with mode of delivery and not with maternal use of selective serotonin reuptake inhibitors. Am J Perinatol 2011; 28 (1): 19-24
18. Kieler H, Artama M, Engeland A, et al. Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries. BMJ 2012; 344: d8012
19. Walsh-Sukys MC, Tyson JE, Wright LL, et al. Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes. Pediatrics 2000; 105 (1): 14-20
20. Levinson-Castiel R, Merlob P, Linder N, et al. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med 2006; 160 (2): 173-6
21. Galbally M, Lewis AJ, Lum J, et al. Serotonin discontinuation syndrome following in utero exposure to antidepressant medication: prospective controlled study. Aust N Z J Psychiatry 2009 Sep; 43 (9): 846-54
22. Gentile S. On categorizing gestational, birth, and neonatal complications following late pregnancy exposure to antidepressants: the prenatal antidepressant exposure syndrome. CNS Spectr 2010; 15 (3): 167-85
23. Oberlander T, Bonaguro R, Misri S, et al. Infant serotonin transporter (SLC6A4) promoter genotype is associated with adverse neonatal outcomes after prenatal exposure to serotonin reuptake inhibitor medications. Mol Psychiatry 2007; 13 (1): 65-73
24. Oberlander TF, Warburton W, Misri S, et al. Effects of timing and duration of gestational exposure to serotonin reuptake inhibitor antidepressants: population-based study. Br J Psychiatry 2008May; 192 (5): 338-43
25. Reynolds EW, Ellington JG, Vranicar M, et al. Brain-type natriuretic peptide in the diagnosis and management of persistent pulmonary hypertension of the newborn. Pediatrics 2004; 114 (5): 1297-304
26. Everson SA, Maty SC, Lynch JW, et al. Epidemiologic evidence for the relation between socioeconomic status and depression, obesity, and diabetes. J Psychosom Res 2002; 53 (4): 891-5
27. Linares Scott TJ, Heil SH, Higgins ST, et al. Depressive symptoms predict smoking status among pregnant women. Addict Behav 2009 Aug; 34 (8): 705-8
28. Malm H, Artama M, Gissler M, et al. Selective serotonin reuptake inhibitors and risk for major congenital anomalies. Obstet Gynecol 2011; 118 (1): 111-20
29. Austin MP, Kildea S, Sullivan E. Maternal mortality and psychiatric morbidity in the perinatal period: challenges and opportunities for prevention in the Australian setting. Med J Aust 2007 Apr 2; 186 (7): 364-7
30. Bansil P, Kuklina EV, Meikle SF, et al. Maternal and fetal outcomes among women with depression. J Womens Health (Larchmt) 2010 Feb; 19 (2): 329-34
31. Brettingham M. Depression and obesity are major causes of maternal death in Britain. BMJ 2004 Nov 20; 329 (7476): 1205
32. Bonari L, Pinto N, Ahn E, et al. Perinatal risks of untreated depression during pregnancy. Can J Psychiatry 2004 Nov; 49 (11): 726-35
33. Kurki T, Hiilesmaa V, Raitasalo R, et al. Depression and anxiety in early pregnancy and risk for preeclampsia. Obstet Gynecol 2000 Apr; 95 (4): 487-90
34. Deave T, Heron J, Evans J, et al. The impact of maternal depression in pregnancy on early child development. BJOG 2008 Jul; 115 (8): 1043-51
35. Nulman I, Rovet J, Stewart DE, et al. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am J Psychiatry 2002 Nov; 159 (11): 1889-95
36. Cohen LS, Altshuler LL, Harlow BL, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 2006 Feb 1; 295 (5): 499-507
37. Yonkers KA, Gotman N, Smith MV, et al. Does antidepressant use attenuate the risk of a major depressive episode in pregnancy? Epidemiology 2011 Nov; 22 (6): 848-54
38. Lund N, Pedersen LH, Henriksen TB. Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcomes. Arch Pediatr Adolesc Med 2009 Oct; 163 (10): 949-54
39. Suri R, Altshuler L, Hellemann G, et al. Effects of antenatal depression and antidepressant treatment on gestational age at birth and risk of preterm birth. Am J Psychiatry 2007 Aug; 164 (8): 1206-13
40. Ramos E, St-Andre M, Berard A. Association between antidepressant use during pregnancy and infants born small for gestational age. Can J Psychiatry 2010 Oct; 55 (10): 643-52
41. Lewis AJ, Galbally M, Opie G, et al. Neonatal growth outcomes at birth and one month postpartum following in utero exposure to antidepressant medication. Aust N Z J Psychiatry 2010 May; 44 (5): 482-7
42. Galbally M, Lewis AJ, Buist A. Developmental outcomes of children exposed to antidepressants in pregnancy. Aust N Z J Psychiatry 2011 May; 45 (5): 393-9
43. Casper RC, Fleisher BE, Lee-Ancajas JC, et al. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr 2003 Apr; 142 (4): 402-8
44. Van den Bergh BR, Van Calster B, Smits T, et al. Antenatal maternal anxiety is related to HPA-axis dysregulation and self-reported depressive symptoms in adolescence: a prospective study on the fetal origins of depressed mood. Neuropsychopharmacology 2008 Feb; 33 (3): 536-45
45. Galbally M, Lewis AJ, Gentile S, et al. The biology of fetal exposure to serotonin reuptake inhibitors: implications for neurodevelopment. In: Migne LJ, Post JW, editors. Antidepressants: pharmacology, health effects and controversy. New York (NY), USA: Nova, 2012: 1-26
46. Van den Bergh BRH, Mulder EJH, Mennes M, et al. Antenatal maternal anxiety and stress and the neurobehavioural development of the fetus and child: links and possible mechanisms. A review. Neurosci Biobehav Rev 2005; 29 (2): 237-58
47. Wisner KL, Sit DKY, Hanusa BH, et al. Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes. Focus 2009; 7 (3): 374-84
48. Fox WW, Duara S. Persistent pulmonary hypertension in the neonate: diagnosis and management. J Pediatr 1983; 103 (4): 505-14
49. Galbally M, Snellen M, Lewis AJ. A review of the use of psychotropic medication in pregnancy. Curr Opin Obstet Gynecol 2011; 23 (6): 408-14
50. Galbally M, Snellen M, Walker S, et al. Management of antipsychotic and mood stabilizer medication in pregnancy: recommendations for antenatal care. Aust N Z J Psychiatry 2010 Feb; 44 (2): 99-108